Readability and content of supplementary written drug information for patients used by Australian rheumatologists

Citation
R. Buchbinder et al., Readability and content of supplementary written drug information for patients used by Australian rheumatologists, MED J AUST, 174(11), 2001, pp. 575-578
Citations number
25
Categorie Soggetti
General & Internal Medicine","Medical Research General Topics
Journal title
MEDICAL JOURNAL OF AUSTRALIA
ISSN journal
0025729X → ACNP
Volume
174
Issue
11
Year of publication
2001
Pages
575 - 578
Database
ISI
SICI code
0025-729X(20010604)174:11<575:RACOSW>2.0.ZU;2-D
Abstract
Objective: To determine the readability and content of supplementary writte n drug information currently being given to patients by rheumatologists in Australia. Design and participants: Blinded standardised review by two independent rev iewers of supplementary written drug information routinely provided to pati ents by the 195 fully registered members of the Australian Rheumatology Ass ociation (ARA). Main outcome measures: FOG and SMOG readability scores to estimate readabil ity; critical appraisal of content according to predetermined criteria. Results: 84 rheumatologists responded (43%), 45 of whom reported providing copies of written drug information to patients. Overall, 91 different docum ents were reviewed. Drugs most commonly considered were methotrexate (17), gold (16), sulfasalazine (10), penicillamine (10) and prednisolone (8). Lev el of agreement between reviewers for FOG and SMOG scores was fair to good (intraclass correlation coefficient, 0.61 and 0.51, respectively). Mean (95 % CI) FOG and SMOG scores were 12.6 (12.2-12.9) and 11 (10.7-11.2), respect ively (implying that half of those in Year 12 [or aged 17 years] and Year 1 1 [or aged 16 years] according to the FOG and SMOG mean scores, respectivel y, will comprehend half of the text or more). For the same medication, ther e was a wide variation in the information provided, including which side ef fects were discussed. While 98% included some information about side effect s, fewer considered dose (74%), drug interactions if applicable (70%), purp ose of drug (67%), how and when to take the drug (62%), expected time to im provement (54%), what to do in the event of side effects (44%), the expecte d duration of therapy (18%) and what to do if a dose was missed (5%). Conclusions: The reading level required to understand supplementary written drug information used by Australian rheumatologists is much higher than th e average reading ability of the Australian population (estimated at Year 8 level). The content of this information varies widely and often omits impo rtant information.